Affinivax: GSK finalizes Affinivax acquisition

GSK (LSE/NYSE:GSK) has wrapped up its acquisition of the privately-held biopharma Affinivax. Cambridge, Massachusetts-based Affinivax has established a vaccine technology platform known as Multiple Antigen Presentation System (MAPS), designed to elicit a strong B-cell and T-cell immune response. GSK was attracted to Affinivax, given its aim to bolster its portfolio of specialty medicines and vaccines. ...The post GSK finalizes Affinivax acquisition appeared first on Pharmaceutical Processing World.